Antibody responses to the merozoite surface protein-1 complex in cerebral malaria patients in India

Naomi W Lucchi1, Jon Eric Tongren, Vidhan Jain

  • 1Malaria Branch, Division of Parasitic Diseases, National Center for Zoonotic, Vector-Borne and Enteric Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. frd9@cdc.gov

Malaria Journal
|July 8, 2008
PubMed
Abstract

Insights

Antibody responses to merozoite surface protein (MSP) antigens are altered in cerebral malaria (CM) patients. Lower antibody levels to specific MSP fragments in CM patients suggest potential immune dysregulation contributing to severe malaria pathogenesis.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Malariology

Background:

  • Plasmodium falciparum infection causes cerebral malaria (CM) in a subset of patients, with current treatments being only partially effective.
  • The exact mechanisms underlying CM development, including neurological sequelae or death, remain unclear.
  • Host immune factors, particularly cellular immunity and cytokines, are thought to influence CM outcomes.

Purpose of the Study:

  • To investigate the relationship between antibody responses to merozoite surface protein (MSP)-1 complex, MSP-6, and MSP-7 antigens and the development of cerebral malaria.
  • To compare antibody profiles in healthy individuals, mild malaria patients, and cerebral malaria patients.

Main Methods:

  • Peripheral blood antibody responses to major allelic forms of MSP-1 complex, MSP-6, and MSP-7 were analyzed.
  • Antibody levels (total IgG and IgG subclasses) were quantified using ELISA in healthy subjects, mild malaria patients (MM), and CM patients from central India.

Main Results:

  • Antibody prevalence and levels varied across different antigens and patient groups.
  • Total IgG, IgG1, and IgG3 levels were generally higher in mild malaria patients compared to healthy controls.
  • CM patients exhibited significantly lower levels of total IgG to MSP-1(f38), IgG1 to MSP-1(d83), MSP-1(19), and MSP-6(36), and IgG3 to MSP-1(f42) and MSP-7(22) compared to MM patients.

Conclusions:

  • Results indicate potential dysregulation in antibody generation against specific MSP antigens in cerebral malaria patients.
  • Further research is warranted to explore if these antibody response perturbations contribute to CM pathogenesis.